Acute Spinal Cord Injury - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Acute Spinal Cord Injury - Pipeline Review, H1 2015', provides an overview of the Acute Spinal Cord Injury's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Spinal Cord Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Spinal Cord Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Spinal Cord Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Spinal Cord Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Acute Spinal Cord Injury Overview 6 Therapeutics Development 7 Pipeline Products for Acute Spinal Cord Injury - Overview 7 Pipeline Products for Acute Spinal Cord Injury - Comparative Analysis 8 Acute Spinal Cord Injury - Therapeutics under Development by Companies 9 Acute Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes 10 Acute Spinal Cord Injury - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Acute Spinal Cord Injury - Products under Development by Companies 13 Acute Spinal Cord Injury - Products under Investigation by Universities/Institutes 14 Acute Spinal Cord Injury - Companies Involved in Therapeutics Development 15 Acorda Therapeutics, Inc. 15 Kringle Pharma, Inc. 16 Neuralstem, Inc. 17 Neuronax SAS 18 Acute Spinal Cord Injury - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 AC-105 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 BA-210 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Cell Therapy for Spinal Cord Injury - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 KP-100IT - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 NSI-566 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 NX-210 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Peptides to Inhibit Major Histocompatibility Complex Class I and II for Central Nervous System and Musculoskeletal Disorders - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Stem Cell Therapy for Acute Spinal Cord Injury - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Acute Spinal Cord Injury - Recent Pipeline Updates 41 Acute Spinal Cord Injury - Dormant Projects 49 Acute Spinal Cord Injury - Product Development Milestones 50 Featured News & Press Releases 50 Nov 26, 2013: NX210 receives Orphan Drug Designation in Europe for the treatment of spinal cord injuries 50 Jan 24, 2013: Acorda Therapeutics Announces Department Of Defense Contract To Support Study Of AC105 In Acute Spinal Cord Injury 50 Oct 15, 2012: Neuronax receives 600.000 euros from Oseo to support its NX210 Project 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables Number of Products under Development for Acute Spinal Cord Injury, H1 2015 7 Number of Products under Development for Acute Spinal Cord Injury - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Products under Investigation by Universities/Institutes, H1 2015 14 Acute Spinal Cord Injury - Pipeline by Acorda Therapeutics, Inc., H1 2015 15 Acute Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H1 2015 16 Acute Spinal Cord Injury - Pipeline by Neuralstem, Inc., H1 2015 17 Acute Spinal Cord Injury - Pipeline by Neuronax SAS, H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 21 Number of Products by Stage and Mechanism of Action, H1 2015 23 Number of Products by Stage and Route of Administration, H1 2015 25 Number of Products by Stage and Molecule Type, H1 2015 27 Acute Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H1 2015 41 Acute Spinal Cord Injury - Dormant Projects, H1 2015 49
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.